Complete Story


FDA Approves Abraxane Plus Gemcitabine for Metastatic Pancreatic Cancer

On Sept. 6, 2013, the U. S. Food and Drug Administration approved paclitaxel protein-bound particles (albumin-bound) (Abraxane® for injectable suspension, Abraxis BioScience, LLC, a wholly owned subsidiary of Celgene Corp.) in combination with gemcitabine for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.  READ MORE